Sources: 1BitterDB, 4ClinicalTrials, 7Cochrane Library, 10DGIdb, 14DrugBank, 29HMDB, 33IUPHAR, 46NDF-RT, 50Novoseek, 56PharmGKB, 68UMLSSee all MalaCards sources |
Drugs for Amyloidosis, Finnish Type (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB): (show top 50)
(show all 90)
| id | | Name | Status | Phase | Clinical Trials | Cas Number | PubChem Id |
|---|
| 1 | | Omega 3 Fatty Acid | Nutraceutical | Phase 4 | 1018 | | | | 2 | | Colchicine | approved | Phase 3, Phase 2, Phase 1 | 115 | 64-86-8 | 6167, 2833 | (S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide 30512-31-3 5843-86-7 64-86-8 7-alpha-H-Colchicine 7.alpha.H-Colchicine 7alphaH-Colchicine AC1L1LXO ACon1_000353 AI3-31149 AKOS001582887 BB_NC-0737 BPBio1_000535 BRD-K00259736-001-06-5 BSPBio_000485 BSPBio_002083 Benzo(a)heptalen-9(5H)-one C 9754 C07592 C22H25NO6 C3915_SIGMA C9754_SIGMA CCRIS 691 CHEBI:27882 CHEMBL107 CID6167 CPD-9785 Colchicin Colchicin [German] Colchicina Colchicina [Italian] Colchicine (JP15/USP) Colchicine (TN) Colchicine [JAN] Colchicine, (+-)-Isomer Colchicine, (R)-Isomer Colchicine, Colchicum autumnale Colchicinum Colchineos Colchisol Colchysat Colcin Colcrys Colsaloid Colstat Condylon D003078 D00570 DB01394 DB08117 DivK1c_000753 EINECS 200-598-5 EU-0100310 Goutnil HMS1569I07 HMS1920A08 HMS2091G16 HMS502F15 HSDB 3044 IDI1_000753 KBio1_000753 KBio2_001322 KBio2_003890 | KBio2_006458 KBio3_001303 KBioGR_000856 KBioSS_001322 Kolkicin LOC LS-279 Lopac0_000310 MEGxp0_001879 MLS001055448 MLS001055448-02 MLS001304089 MLS002153786 MPC-004 MolPort-001-742-594 N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)- acetamide N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)acetamide N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[.alpha.]heptalen-7-yl)-acetamide N-Acetyl trimethylcolchicinic acid methylether N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide N-[(7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide NCGC00025125-01 NCGC00025125-02 NCGC00025125-03 NCGC00025125-04 NCGC00025125-05 NCGC00025125-06 NCGC00025125-07 NCGC00025125-11 NCGC00169157-01 NCGC00169157-02 NCGC00169157-03 NCI60_041659 NChemBio.2007.10-comp20 NINDS_000753 NSC 757 NSC757 Prestwick0_000363 Prestwick1_000363 Prestwick2_000363 Prestwick3_000363 Prestwick_695 S2284_Selleck SDCCGMLS-0066633.P001 SMR000058323 SPBio_000289 SPBio_002406 SPECTRUM1500205 Spectrum2_000075 Spectrum3_000362 Spectrum4_000298 Spectrum5_000787 Spectrum_000842 Tocris-1364 UNII-SML2Y3J35T UPCMLD-DP065 UPCMLD-DP065:001 WLN: L B677 MV&T&J CO1 DO1 EO1 JMV1 NO1 ZINC00621853 binds to tubulin colchicine inhibits microtubular assembly nchembio853-comp2 spindle poison |
| | 3 | | Bortezomib | approved, investigational | Phase 3 | 807 | 179324-69-7 | 387447, 93860 | 179324-69-7 AC1L8TUW Bortezomib Bortezomib (JAN/USAN/INN) CHEBI:287372 CHEBI:41143 CHEMBL325041 CID387447 D03150 DB07475 DPBA FT-0082488 I14-3268 LDP-341 LDP341 LPD 341 LPD-341 | MLN341 MolPort-003-845-298 N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide NCI60_029010 NSC-681239 NSC681239 PROSCRIPT BORONIC ACID PS-341 Pyz-Phe-boroLeu S1013_Selleck SBB071337 Velcade Velcade (TN) Velcade, MG-341, PS-341, Bortezomib [(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid bortezomib |
| | 4 | | Mechlorethamine | approved | Phase 3 | 397 | 51-75-2 | 4033 | .Beta.,.beta.'-Dichlorodiethyl-N-methylamine 1, 5-Dichloro-3-methyl-3-azapentane hydrochloride 126-85-2 (N-oxide) 2,2'-Dichloro-N-me 2,2'-Dichloro-N-methyldiethylamine 2,2'-Dichlorodiethyl-methylamine 2,2'-dichloro-N-methyldiethylamine 2-Chloro-N-(2-chloroethyl)-N-methylethanamine 302-70-5 (N-oxide, hydrochloride) 51-75-2 55-86-7 (HYDROCHLORIDE) AC1L1H9H Antimit BRN 0605323 BSPBio_001947 Bis(2-chloroethyl)methylamine Bis(beta-chloroethyl) methylamine Bis(beta-chloroethyl)methylamine C07115 C5H11Cl2N CCRIS 447 CHEBI:28925 CHEMBL427 CID4033 Carolysine Caryolysin Caryolysine Chloramine (the nitrogen mustard) Chlorethazine Chlormethine Chlormethine (INN) Chlormethine [INN:BAN] Chlormethinum [INN-Latin] Cloramin Clormetina Clormetina [INN-Spanish] D07671 DB00888 Di(2-chloroethyl)methylamine Dichlor amine Dichloren DivK1c_000759 EINECS 200-120-5 ENT-25294 Embechine Embichin HMS1920J15 HMS2091B04 HMS502F21 HN-2 HN2 HSDB 5083 I14-8708 IBS-L0033631 IDI1_000759 KBio1_000759 KBio2_001369 KBio2_003937 KBio2_006505 KBio3_001447 | KBioGR_001448 KBioSS_001369 LS-7559 MBA Me chloroethamine Mebichloramine Mechlorethamine Mechlorethanamine Mechloroethamine Mecloretamina Mecloretamina [Italian] Methylbis(2-chloroethyl)amine Methylbis(beta-chloroethyl)amine Methyldi(2-chloroethyl)amine Mitoxine (*Hydrochloride*) MolPort-001-785-592 Mustargen Mustine Mustine note Mutagen N,N-Bis(2-chloroethyl)-N-methylamine N,N-Bis(2-chloroethyl)methylamine N,N-Di(chloroethyl)methylamine N-Lost N-Methyl lost N-Methyl-2,2'-dichlorodiethylamine N-Methyl-bis(2-chloroethyl)amine N-Methyl-bis(beta-chloroethyl)amine N-Methyl-bis-chloraethylamin N-Methyl-bis-chloraethylamin [German] N-Methyl-lost N-Methyl-lost [German] N-methyl-bis(2-chloroethyl)amine NCGC00091835-02 NCGC00091835-03 NCGC00091835-04 NCGC00091835-05 NCI60_041682 NINDS_000759 NSC762 Nitol (*Hydrochloride*) Nitrogen mustard Nitrogen mustard (HN-2) Nitrogranulogen SPBio_000496 SPECTRUM1500375 Spectrum2_000448 Spectrum3_000484 Spectrum4_000924 Spectrum5_001702 Spectrum_000889 Stickstofflost (*Hydrochloride*) Stickstofflost (ebewe) T 1024 T-1024 TL 146 UNII-50D9XSG0VR beta,Beta'-dichlorodiethyl-N-methylamine beta,beta'-Dichlorodiethyl-N-methylamine mechlorethamine thyldiethylamine β,β'-dichlorodiethyl-N-methylamine |
| | 5 | | Melphalan | approved | Phase 3 | 729 | 148-82-3 | 4053, 460612 | (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid 148-82-3 3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine 3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine 3025 C.B. 3025 c.b 3223-07-2 4-(Bis(2-chloroethyl)amino)-L-phenylalanine 4-14-00-01689 (Beilstein Handbook Reference) 4-[Bis(2-chloroethyl)amino]-L-phenylalanine 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine AC1LA2OE ALKERAN (TN) AY3360000 Alanine Nitrogen Mustard Alkeran AmbotzHAA1563 At-290 BIDD:GT0044 BRD-K87827419-001-02-8 BRN 2816456 BSPBio_002407 C13H18Cl2N2O2 CB 3025 CB-3025 CCRIS 374 CHEBI:165415 CHEBI:28876 CHEMBL852 CID460612 D00369 DivK1c_000653 EINECS 205-726-3 HMS2090B09 HMS2091B16 HMS502A15 HSDB 3234 IDI1_000653 KBio1_000653 KBio2_000877 KBio2_003445 KBio2_006013 KBio3_001627 KBioGR_001284 KBioSS_000877 L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine L-PAM L-Phenylalanine mustard L-Sarcolysin L-Sarcolysine L-Sarkolysin LS-15868 LS-865 | Levofalan Levofolan Levopholan M2011_SIGMA MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)) MLS001333666 MLS002153368 Melfalan Melfalano Melfalano [INN-Spanish] Melphalan (JP15/USP/INN) Melphalan [USAN:INN:BAN:JAN] Melphalanum Melphalanum [INN-Latin] Mephalan MolPort-003-665-535 NCGC00090757-01 NCGC00090757-02 NCGC00090757-03 NCI-C04853 NINDS_000653 NIOSH/AY3360000 NSC 241286 NSC 8806 NSC-8806 NSC241286 NSC8806 P-Di-(2-chloroethyl)amino-L-phenylalanine P-L-Sarcolysin P-N-Bis(2-chloroethyl)amino-L-phenylalanine Phenylalanine mustard Phenylalanine nitrogen mustard Prestwick_1006 RCRA waste no. U150 Rcra waste number U150 SK-15673 SMP2_000174 SMR000058720 SPBio_000287 SPECTRUM1500382 Sarcolysine Sarkolysin Spectrum2_000074 Spectrum3_000684 Spectrum4_000882 Spectrum5_001601 Spectrum_000397 TL8001065 TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN) TRANSGENIC MODEL EVALUATION (MELPHALAN) UNII-Q41OR9510P melphalan p-Bis(beta-chloroethyl)aminophenylalanine p-Di-(2-chloroethyl)amino-L-phenylalanine p-L-Sarcolysin p-L-sarcolysine p-N,N-bis(2-chloroethyl)amino-L-phenylalanine p-N-Bis(2-chloroethyl)amino-L-phenylalanine p-N-Di(chloroethyl)aminophenylalanine p-N-di(chloroethyl)aminophenylala nine phenylalanine nitrogen mu stard |
| | 6 | | Triamcinolone | approved, vet_approved | Phase 3, Phase 2 | 510 | 124-94-7 | 31307 | (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione 11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione 11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione 124-94-7 4-08-00-03629 (Beilstein Handbook Reference) 83474-03-7 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 9-alpha-Fluoro-16-alpha-hydroxyprednisolone 9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy 9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione 9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 9alpha-Fluoro-16alpha-hydroxyprednisolone 9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione 9α-fluoro-16α-hydroxyprednisolone AC-2072 AC1L1LDH AC1Q5HJC Adcortyl Aristocort Aristocort A Aristocort Tablets Aristogel Aristospan Azmacort BPBio1_000154 BRD-K77554836-001-03-3 BRN 2341955 BSPBio_000140 Bio-0662 C21H27FO6 CHEMBL1451 CID31307 CL 19823 Celeste Cinolone Cinolone-T D00385 D014221 DB00620 Delphicort EINECS 204-718-7 EU-0101179 Fluoxiprednisolone Fluoxyprednisolone Flutex Fougera HMS1568G22 HMS2090D12 HSDB 3194 Kenacort Kenacort (TN) Kenacort-A Kenacort-AG Kenacort-Ag Kenalog Kenalog in Orabase Kenalog-10 Kenalog-40 Kenalog-H LS-698 Ledercort Lopac0_001179 | MLS000028542 MLS001066543 MLS002695935 MolPort-002-528-981 Mycolog NCGC00021580-03 NCGC00021580-04 NCGC00021580-05 NCGC00021580-06 NCGC00021580-07 NCI60_000750 NSC 13397 NSC13397 Nasacort Nasacort Aq Nasacort Hfa Omcilon Omicilon Oracort Oralone Orion Polcortolon Pregna-1,4-diene-3,20-dio Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha) Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI) Prestwick0_000120 Prestwick1_000120 Prestwick2_000120 Prestwick3_000120 Prestwick_438 Rodinolone S1933_Selleck SK-Triamcinolone SMP1_000300 SMR000058333 SPBio_002079 Sk-Triamcinolone T6376_SIGMA TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7)) Tiamcinolonum Tiamcinolonum [INN-Latin] Tri-Nasal Triacet Triacort Triam-Tablinen Triamcet Triamcinalone Triamcinlon Triamcinolon Triamcinolona Triamcinolona [INN-Spanish] Triamcinolone (JP15/USP/INN) Triamcinolone [USAN:INN:BAN:JAN] Triamcinolone acetonide Triamcinolone diacetate Triamcinolone hexacetonide Triamcinolonum Triamcinolonum [INN] Triatex Tricortale Triderm Trilone Tristoject Trymex UNII-1ZK20VI6TY Vetalog Volon Volon A WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ ZINC03882036 droxypregna-1,4-diene-3,20-dione ione nchembio.2007.53-comp7 triamcinolone | |
| | 7 | | Diflunisal | approved | Phase 2, Phase 3 | 4 | 22494-42-4 | 3059 | 1FL 2',4'-Difluoro-4-hydroxy-(1,1'-biphenyl)-3-carboxylic acid 2',4'-Difluoro-4-hydroxy-3-biphenylcarboxylic acid 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid 2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid 22494-42-4 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID 5-(2,4-Difluorophenyl)salicylic acid 5-(2,4-difluorophenyl)-2-hydroxybenzoic acid 5-[2,4-Difluorophenyl]salicylic acid AB00051969 AC1L1F2Z Adomal Algobid Apo-Diflunisal Apotex Brand of Diflunisal BIDD:GT0063 BPBio1_000151 BRD-K22031190-001-05-3 BRN 2654431 BSPBio_000137 BSPBio_002203 C01691 C13H8F2O3 CAS-22494-42-4 CHEBI:39669 CHEMBL898 CID3059 CPD000058723 Cahill May Roberts Brand of Diflunisal Citidol D00130 D004061 D3281_FLUKA D3281_SIGMA DB00861 DB06895 Difludol Diflunisal Diflunisal (JAN/USP/INN) Diflunisal Novopharm Brand Diflunisal [USAN:INN:BAN:JAN] Diflunisalum Diflunisalum [INN-Latin] DivK1c_000938 Dolisal Dolobid Dolobid (TN) Dolobil Dolobis Dolocid EINECS 245-034-9 Flovacil Fluniget Fluodonil | Flustar Frosst SA Brand of Diflunisal HMS1568G19 HMS1920G10 HMS2090C16 HMS2091M20 HMS502O20 I01-3451 IDI1_000938 KBio1_000938 KBio2_001442 KBio2_004010 KBio2_006578 KBio3_001423 KBioGR_001085 KBioSS_001442 LS-44258 MK 647 MK-647 MK647 MLS000028678 MLS001146895 Merck Brand of Diflunisal Merck Sharp & Dohme Brand of Diflunisal MolPort-001-727-460 NCGC00016765-01 NCGC00016765-02 NCGC00022783-03 NCGC00022783-04 NINDS_000938 Noaldol Novo-Diflunisal Novopharm Brand of Diflunisal Nu Pharm Brand of Diflunisal Nu-Diflunisal Nu-Pharm Brand of Diflunisal Prestwick0_000039 Prestwick1_000039 Prestwick2_000039 Prestwick3_000039 Prestwick_168 Reuflos SAM002554896 SBB058143 SMR000058723 SPBio_001163 SPBio_002058 SPECTRUM1500245 Spectrum2_001012 Spectrum3_000392 Spectrum4_000513 Spectrum5_000901 Spectrum_000962 UNII-7C546U4DEN Unisal diflunisal | |
| | 8 | | Dexamethasone | approved, investigational, vet_approved | Phase 3 | 2171 | 50-02-2 | 5743 | (3H)-Dexamethasone .delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol .gamma.corten 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone 1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone 1-Dehydro-16α-methyl-9α-fluorohydrocortisone 137098-19-2 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone 16-alpha-Methyl-9-alpha-fluoroprednisolone 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol 16.alpha.-Methyl-9.alpha.-fluoroprednisolone 16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol 16alpha -Methyl-9alpha -fluoroprednisolone 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone 16alpha-Methyl-9alpha-fluoroprednisolone 16α-Methyl-9α-fluoro-1-dehydrocortisol 23495-06-9 31375_FLUKA 46165_FLUKA 46165_RIEDEL 50-02-2 8054-59-9 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione 9-Fluoro-16-methylprednisolone 9-alpha-Fluoro-16-alpha-methylprednisolone 9.alpha.-Fluoro-16.alpha.-methylprednisolone 906422-84-2 9A-FLUORO-16BETA-METHYLPREDNISOLONE 9alpha -Fluoro-16alpha -methylprednisolone 9alpha-Fluoro-16alpha-methylprednisolone 9alpha-fluoro-16alpha-methyl-Prednisolone 9α-Fluoro-16α-methylprednisolone AC-11056 AC1L1L1H AC1Q29DM AI3-50934 Adexone Aeroseb-D Aeroseb-Dex Aeroseb-dex Ak Dex Oph Otic Soln 0.1% Alcon Brand of Dexamethasone Anaflogistico Aphtasolon Aphthasolone Apo-dexamethasone Auxiron Azimycin (veterinary) Azium Azium (Veterinary) Azium (veterinary) BIDD:ER0494 BIDD:PXR0060 BRD-K38775274-001-02-3 BRD-K38775274-001-06-4 BSPBio_000995 Bisu DS Bisu Ds C15643 C22H29FO5 CCRIS 7067 CHEBI:41879 CHEMBL384467 CID5743 CPD-10549 CPD001227192 Calonat Corson Corsone Cortisumman D00292 D003907 D1756_SIGMA D4902_SIGMA D6645_SIGMA D8893_SIGMA D9184_SIGMA DB01234 DEX DEXA DEXONE 0.5 DEXONE 0.75 DEXONE 1.5 DEXONE 4 DXM DXMS Decacort Decacortin Decaderm Decadron Decadron (TN) Decadron Tablets, Elixir Decadron, Dexamethasone Decadron-LA Decadron-La Decagel Decaject Decaject L.A. Decaject-L.A. Decalix Decameth Decasone Decaspray Dectancyl Dekacort Delta1-9alpha-Fluoro-16alpha-methylcortisol Deltafluorene Dergramin Deronil Desadrene Desametasone Desametasone [DCIT] Desametasone [Dcit] Desamethasone Desameton Deseronil Dex-Ide Dex-ide Dexa Dexa Mamallet Dexa mamallet Dexa-Cortidelt Dexa-Cortisyl Dexa-Mamallet Dexa-Scheroson Dexa-Sine Dexa-cortidelt Dexa-cortisyl Dexa-scheroson Dexa-sine Dexacen-4 Dexacidin Dexacort Dexacortal Dexacortin Dexadeltone Dexafarma Dexair Dexalona Dexaltin Dexametasona Dexametasona [INN-Spanish] Dexametasone | Dexameth Dexamethansone Dexamethasone Dexamethasone (JP15/USP/INN) Dexamethasone Acetate Dexamethasone Alcohol Dexamethasone Base Dexamethasone Intensol Dexamethasone Sodium Phosphate Dexamethasone [INN:BAN:JAN] Dexamethasone alcohol Dexamethasone base Dexamethasone intensol Dexamethasone-omega Dexamethasonum Dexamethasonum [INN-Latin] Dexamethazone Dexamonozon Dexapolcort Dexapos Dexaprol Dexason Dexasone Dexasone 0.5mg Dexasone 0.75mg Dexasone 4mg Dexasporin Dexinolon Dexinoral Dexone Dexone 0.5 Dexone 0.75 Dexone 1.5 Dexone 4 Dexonium Dexpak Dextelan Dezone Dinormon Dxms ECR Brand of Dexamethasone EINECS 200-003-9 FT-0080377 Fluormethylprednisolone Fluormone Fluorocort Fortecortin Foy Brand of Dexamethasone Gammacorten HL-dex HMS1792A17 HMS1990A17 HMS2089N13 HSDB 3053 Hexadecadrol Hexadrol Hexadrol Elixir Hexadrol Tablets Hexadrol elixir Hl-Dex Hl-dex I06-1196 ICN Brand of Dexamethasone IontoDex Isopto-Dex Isopto-dex LS-7300 Lokalison F Lokalison f Loverine Luxazone MK 125 MLS001055412 MLS001332507 MLS001332508 Maxidex Maxidex Ont 0.1% Maxidex Sus 0.1% Maxitrol Mediamethasone Merck Brand of Dexamethasone Merz Brand 1 of Dexamethasone Merz Brand 2 of Dexamethasone Methylfluorprednisolone Mexidex Millicorten MolMap_000018 MolPort-003-846-433 Mymethasone NCGC00091019-01 NCGC00091019-02 NCGC00091019-03 NCGC00091019-04 NCGC00091019-05 NCI60_003067 NSC 34521 NSC34521 Naquasone (veterinary) Neomycin and polymyxin b sulfates and dexamethasone Neomycin and polymyxin b sulphates and dexamethasone OTO-104 Ocu-Trol Ocu-trol Oradexon PHL-dexamethasone PMS-dexamethasone Pet Derm III Pet Derm Iii Pet derm III Pet-Derm Iii Pms Dexamethasone Elixir 0.5mg/5ml Policort Posurdex Prednisolon F Prednisolon f Prednisolone F Prednisolone f Prodex S1322_Selleck SAM002548948 SGCUT00126 SK-Dexamethasone SK-dexamethasone SMP1_000092 SMR000857119 SMR001227192 ST50307091 Sandoz dexamethasone Sk-Dexamethasone Spectrum5_002019 Spoloven Sunia Sol D Sunia sol D Superprednol TL8003317 Tobradex Tobramycin and dexamethasone Tresaderm (veterinary) Turbinaire UNII-7S5I7G3JQL Visumetazone WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1 ZINC03875332 alpha -Fluoro-16-alpha -methylcortisol delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol delta1-9alpha-Fluoro-16alpha-methylcortisol dexamethasone nchembio809-comp2 to_000038 |
| | 9 | | Bicalutamide | approved | Phase 3 | 176 | 90357-06-5 | 56069, 2375 | (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide 90357-06-5 AC-4232 AC1L1DJE Astra brand of bicalutamide AstraZeneca brand of bicalutamide BRN 5364666 Bicalutamida Bicalutamide Bicalutamide (JAN/USP/INN) Bicalutamide [USAN:INN:BAN] Bicalutamidum C053541 C08160 C18H14F4N2O4S CHEMBL409 CID2375 CPD000466329 Casodex Casodex (TN) Casodex, Cosudex, Calutide, Kalumid, Bicalutamide Cosudex D00961 DB01128 | FT-0080576 HMS2051B13 HMS2089N12 I06-0475 I06-0480 ICI 176334 ICI-176334 KS-1161 LS-119125 MLS000759437 MLS001424047 MolPort-003-845-034 MolPort-006-808-679 N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide NCGC00167977-01 NCGC00167977-02 NSC722665 Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-, Raffolutil S1190_Selleck SAM001246612 SMR000466329 TL8005814 Zeneca brand of bicalutamide bicalutamide propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-,(+-) | |
| | 10 | | Goserelin | approved | Phase 3 | 233 | 65807-02-5 | 47725, 5311128 | (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide AC1NSK1T CID5311128 Goserelin Goserelin acetate | HMS2089D16 HS-2015 ICI-118630 MolPort-006-823-831 ZD-9393 Zoladex goserelin |
| | 11 | | Buserelin | approved | Phase 3 | 31 | 57982-77-1 | | (Des-Gly10,D-Ser(tBu)6,Pro-NHEt9)-LHRH | D-Ser(Tbu)6EA10LHRH Etilamide Tiloryth |
| | 12 | | Leuprolide | approved, investigational | Phase 3 | 299 | 53714-56-0 | 3911, 657181 | (D-Leu(6),des-gly-NH2(10),pro-ethylamide(9))-gonadotropin-releasing hormone 5-oxoPro-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-ProNHC2H5 dihydrate 5-oxoprolylhistidyltryptophylseryltyrosylleucylleucyl-n5-(diaminomethylidene)ornithyl-n-ethylprolinamide AC1L1GZK AC1L9B44 AC1Q5OPO AR-1G9354 C07612 CID3911 CID441410 D00989 D08113 Enantone Enantone (TN) I04-0109 L-Pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide L001094 | L002030 Leuprolide Leuprolide acetate Leuprolide acetate (USAN) Leuprorelin Leuprorelin (INN) Leuprorelin acetate (JAN) Leuprorelina Leuproreline Leuprorelinum Lupron (TN) N-[1-[[1-[[1-[[1-[[1-[[1-[[5-(diaminomethylideneamino)-1-[2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide NSC377526 NSC746847 PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-NHC2H5 PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-nhet acetic acid leuprolide | |
| | 13 | | Flutamide | approved | Phase 3 | 64 | 13311-84-7 | 3397 | .alpha.,.alpha.,.alpha.-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide 13311-84-7 1A Brand of Flutamide 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide 337962-98-8 37209-54-4 4'-Nitro-3'-(trifluoromethyl)isobutyranilide 4'-Nitro-3'-trifluoromethylisobutyramilide 4'-Nitro-3'-trifluoromethylisobutyranilide 4-Nitro-3-(trifluoromethyl)isobutyranilide AB00052188 AC-10517 AC1L1FUE AKOS001025465 Alphapharm Brand of Flutamide Apimid Apo Flutamide Apo-Flutamide ApoFlutamide Apogepha Brand of Flutamide Apotex Brand of Flutamide Azupharma Brand of Flutamide BPBio1_000087 BRD-K28307902-001-05-0 BRN 2157663 BSPBio_000079 BSPBio_003122 C07653 C11H11F3N2O3 CAS-13311-84-7 CCRIS 7246 CHEBI:5132 CHEMBL806 CID3397 CPD000058187 Cebatrol Cebatrol, veterinary Chephasaar Brand of Flutamide Chimax Chiron Brand of Flutamide Ciclum Brand of Flutamide Cytamid D005485 D00586 DB00499 DivK1c_000459 Drogenil EINECS 236-341-9 ETHINYL ESTRADIOL) EU-0100557 Essex Brand of Flutamide Eulexin Eulexin (TN) Eulexin, Flutamin, Drogenil,Flutamide Eulexine F 9397 F0663 F9397_SIGMA FTA Fluken Flulem Flumid Fluta 1A Pharma Fluta GRY Fluta cell Fluta-GRY Fluta-cell FlutaGRY Flutacell Flutamid Flutamida Flutamida [INN-Spanish] Flutamide Flutamide (JAN/USP/INN) Flutamide (pubertal study) Flutamide USP25 Flutamide [USAN:BAN:INN] Flutamidum Flutamidum [INN-Latin] Flutamin Flutandrona Flutaplex Flutexin Fugerel Gry Brand of Flutamide HMS1568D21 HMS1921O16 HMS2090I18 HMS2092O14 HMS501G21 Ham's F-12 medium Hexal Brand of Flutamide | I01-2470 IDI1_000459 Inibsa Brand of Flutamide Ipsen Brand of Flutamide Juta Brand of Flutamide KBio1_000459 KBio2_001690 KBio2_004258 KBio2_006826 KBio3_002342 KBioGR_001377 KBioSS_001690 Kendrick Brand of Flutamide LS-2105 Lemery Brand of Flutamide Lopac-F-9397 Lopac0_000557 METHOXYCHLOR MLS000069634 MLS001065596 MolPort-001-771-894 NCGC00015452-01 NCGC00015452-02 NCGC00015452-04 NCGC00015452-12 NCGC00091460-01 NCGC00091460-02 NCGC00091460-03 NCGC00091460-04 NCGC00091460-05 NCGC00091460-06 NCGC00091460-07 NCGC00091460-08 NCGC00091460-09 NFBA NINDS_000459 NK-601 NSC 215876 NSC147834 NSC215876 Niftholide Niftolid Niftolide Novo Flutamide Novo-Flutamide NovoFlutamide Novopharm Brand of Flutamide Odyne Oncosal PMS Flutamide PMS-Flutamide PUBERTAL FLUTAMIDE STUDY (PUBERTAL STUDIES OF VINCLOZOLIN Pharmascience Brand of Flutamide Prasfarma Brand of Flutamide Prestwick0_000180 Prestwick1_000180 Prestwick2_000180 Prestwick3_000180 Prestwick_228 Prostacur Prostandril Prostica Prostogenat Q Pharm Brand of Flutamide Q-Pharm Brand of Flutamide S1908_Selleck SAM002264612 SCH13521 SMR000058187 SPBio_000982 SPBio_002000 SPECTRUM1500995 ST058409 Sch 13521 Sch-13521 Schering Brand of Flutamide Schering Plough Brand of Flutamide Schering-Plough Brand of Flutamide Spectrum2_001201 Spectrum3_001421 Spectrum4_000829 Spectrum5_001450 Spectrum_001210 TAD Brand of Flutamide Tedec Meiji Brand of Flutamide Testotard UNII-76W6J0943E ZINC03812944 alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide cell pharm Brand of Flutamide esparma Brand of Flutamide flutamide m-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro- (8CI) m-propionotoluidide,alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro niftolid | |
| | 14 | | Ginseng | approved, nutraceutical | Phase 3 | 96 | 50647-08-0 | | Aralia ginseng root Asian ginseng Asian ginseng root Chinese ginseng root Ginseng (panax ginseng) Ginseng extract Ginseng, asian Hong shen root Insam root Korean ginseng | Korean ginseng root Ninjin root Panax ginseng Panax ginseng root Panax ginseng root extract Panax schinseng root Panax verus root Red ginseng Ren seng root Ren shen Ren shen root True ginseng root |
| | 15 | | Antimitotic Agents | | Phase 3, Phase 2, Phase 1 | 5657 | | | | 16 | | Antirheumatic Agents | | Phase 2, Phase 3, Phase 1 | 10956 | | | | 17 | | Anti-Inflammatory Agents, Non-Steroidal | | Phase 2, Phase 3 | 4443 | | | | 18 | | Hormones, Hormone Substitutes, and Hormone Antagonists | | Phase 3, Phase 2 | 13168 | | | | 19 | | Hormones | | Phase 3, Phase 2 | 14415 | | | | 20 | | Anti-Inflammatory Agents | | Phase 2, Phase 3 | 10729 | | | | 21 | | Immunosuppressive Agents | | Phase 3, Phase 2 | 13086 | | | | 22 | | Triamcinolone diacetate | | Phase 3, Phase 2 | 510 | | | | 23 | | Triamcinolone hexacetonide | | Phase 3, Phase 2 | 510 | | | | 24 | | Analgesics | | Phase 2, Phase 3 | 11733 | | | | 25 | | Hormone Antagonists | | Phase 3, Phase 2 | 13180 | | | | 26 | | triamcinolone acetonide | | Phase 3, Phase 2 | 510 | | | | 27 | | Analgesics, Non-Narcotic | | Phase 2, Phase 3 | 6501 | | | | 28 | | protease inhibitors | | Phase 3 | 5471 | | | | | 29 | | glucocorticoids | | Phase 3, Phase 2 | 5103 | | | | 30 | | Vaccines | | Phase 3 | 6611 | | | | 31 | | Alkylating Agents | | Phase 3 | 4827 | | | | 32 | | Antiemetics | | Phase 3 | 4022 | | | | 33 | | Immunoglobulins | | Phase 3, Phase 2, Phase 1 | 6394 | | | | 34 | | Antibodies, Monoclonal | | Phase 3, Phase 2, Phase 1 | 4039 | | | | 35 | | Cyclooxygenase Inhibitors | | Phase 2, Phase 3 | 2870 | | | | 36 | | Interleukin 1 Receptor Antagonist Protein | | Phase 3, Phase 2, Phase 1 | 99 | | | | 37 | | Antibodies | | Phase 3, Phase 2, Phase 1 | 6394 | | | | 38 | | HIV Protease Inhibitors | | Phase 3 | 5470 | | | | 39 | | Antineoplastic Agents, Alkylating | | Phase 3 | 4603 | | | | 40 | | Dexamethasone acetate | | Phase 3 | 2171 | 1177-87-3 | | | 41 | | Gastrointestinal Agents | | Phase 3, Phase 2, Phase 1 | 8402 | | | | 42 | | Peripheral Nervous System Agents | | Phase 2, Phase 3 | 23689 | | | | 43 | | Dexamethasone 21-phosphate | | Phase 3 | 2171 | | | | 44 | | BB 1101 | | Phase 3 | 2171 | | | | 45 | | Antineoplastic Agents, Hormonal | | Phase 3 | 5592 | | | | 46 | | Autonomic Agents | | Phase 3 | 10150 | | | | 47 | | Pharmaceutical Solutions | | Phase 3, Phase 2 | 8192 | | | | 48 | | Triptorelin Pamoate | | Phase 3 | 169 | | | | 49 | | Androgens | | Phase 3 | 1321 | | | | 50 | | Androgen Antagonists | | Phase 3 | 320 | | |
Interventional clinical trials: (show top 50)
(show all 86)
| id | Name | Status | NCT ID | Phase |
|---|
| 1 | Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels | Terminated | NCT00578578 | Phase 4 | | 2 | The Effect of Diflunisal on Familial Amyloidosis | Completed | NCT00294671 | Phase 2, Phase 3 | | 3 | Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis | Completed | NCT00409175 | Phase 2, Phase 3 | | 4 | ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) | Completed | NCT02319005 | Phase 3 | | 5 | An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy | Completed | NCT00791492 | Phase 2, Phase 3 | | 6 | The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin | Completed | NCT01435655 | Phase 3 | | 7 | Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis | Completed | NCT00035334 | Phase 2, Phase 3 | | 8 | Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever | Completed | NCT01705756 | Phase 3 | | 9 | Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease | Completed | NCT01576367 | Phase 3 | | 10 | Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis | Completed | NCT01078454 | Phase 3 | | 11 | Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease | Completed | NCT01302860 | Phase 3 | | 12 | The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada | Completed | NCT01105507 | Phase 3 | | 13 | An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes | Completed | NCT02911857 | Phase 3 | | 14 | Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome | Completed | NCT00465985 | Phase 3 | | 15 | Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study. | Completed | NCT01080131 | Phase 3 | | 16 | Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) | Completed | NCT00288704 | Phase 3 | | 17 | American Ginseng in Treating Patients With Fatigue Caused by Cancer | Completed | NCT00719563 | Phase 3 | | 18 | A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies | Recruiting | NCT02334748 | Phase 3 | | 19 | A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) | Recruiting | NCT03114657 | Phase 3 | | 20 | APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis | Active, not recruiting | NCT01960348 | Phase 3 | | 21 | Efficacy and Safety of IONIS-TTR Rx in Familial Amyloid Polyneuropathy | Active, not recruiting | NCT01737398 | Phase 3 | | 22 | Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. | Active, not recruiting | NCT01760005 | Phase 2, Phase 3 | | 23 | Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers | Active, not recruiting | NCT02059291 | Phase 3 | | 24 | Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer | Active, not recruiting | NCT00567580 | Phase 3 | | 25 | Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP) | Enrolling by invitation | NCT02175004 | Phase 3 | | 26 | The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran) | Enrolling by invitation | NCT02510261 | Phase 3 | | 27 | Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation | Unknown status | NCT02175589 | Phase 2 | | 28 | Study of SOM0226 in Familial Amyloid Polyneuropathy | Completed | NCT02191826 | Phase 1, Phase 2 | | 29 | Safety and Effect of Doxycycline in Patients With Amyloidosis | Completed | NCT01677286 | Phase 2 | | 30 | The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant | Completed | NCT02595983 | Phase 2 | | 31 | Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis | Completed | NCT01171859 | Phase 2 | | 32 | The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis | Completed | NCT00630864 | Phase 2 | | 33 | Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy | Completed | NCT01821118 | Phase 2 | | 34 | Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis | Completed | NCT02016365 | Phase 2 | | 35 | Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy | Completed | NCT00056238 | Phase 2 | | 36 | The Study of an Investigational Drug, ALN-TTR02 (Patisiran), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran) | Completed | NCT01961921 | Phase 2 | | 37 | Rilonacept for Treatment of Familial Mediterranean Fever (FMF) | Completed | NCT00582907 | Phase 2 | | 38 | Interleukin-1 Trap to Treat Autoinflammatory Diseases | Completed | NCT00094900 | Phase 2 | | 39 | Ascending Single Dose Study of Rhu-pGelsolin in Patients With Decreased Gelsolin Levels | Completed | NCT00671307 | Phase 1, Phase 2 | | 40 | F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis | Recruiting | NCT02414230 | Phase 2 | | 41 | A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis | Recruiting | NCT03002974 | Phase 2 | | 42 | Tolerability and Efficacy of a Combination of Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy | Active, not recruiting | NCT01855360 | Phase 1, Phase 2 | | 43 | A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease | Active, not recruiting | NCT02167256 | Phase 2 | | 44 | Probiotics and Corticosteroids for Treating Periodic Fever, Aphthous Stomatitis, Pharyngitis, Cervical Adenitis (PFAPA) | Not yet recruiting | NCT02535962 | Phase 2 | | 45 | Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration | Terminated | NCT01577381 | Phase 2 | | 46 | The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria | Completed | NCT00214851 | Phase 1 | | 47 | Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients | Completed | NCT01075906 | Phase 1 | | 48 | Health Evaluation in African Americans Using RAS Therapy | Recruiting | NCT02471833 | Phase 1 | | 49 | A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects | Active, not recruiting | NCT02797847 | Phase 1 | | 50 | Ilaris (Canakinumab) in Patient With Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA) | Not yet recruiting | NCT02775994 | Phase 1 |
|
